Alerta

LEVAN-CATECHOL COMPOSITE, AND TISSUE ADHESION COMPOSITION AND NANOCLUSTER INCLUDING SAME

Resumen de: US20260108656A1

The present invention relates to a levan-catechol composite, and a tissue adhesion composition and nanocluster, including same. In particular, the levan-catechol composite is prepared by the conjugation of levan and catechol and is applicable, by hydrogelation or nanoclustering thereof, for use in tissue adhesion in wet environments, wound healing, hemostasis, or drug delivery.

LIPID AMINES

Resumen de: US20260109732A1

Provided are lipid amine compounds which are useful in the preparation of lipid nanoparticle compositions for delivery of therapeutic or prophylactic payload into cells.

SELF-ASSEMBLED MUCOADHESIVE BIOPOLYMER PARTICLE RELEASE SYSTEM AND PREPARATION METHOD THEREOF

Resumen de: US20260108615A1

0000 The present invention relates to a mucoadhesive polymeric prodrug comprising a partially succinated polyvinyl alcohol (PVA-SA) with adjusted amount of hydroxyl and carboxyl pendant groups, which form an ester and/or amide linkage with amino and/or carboxyl and/or hydroxyl groups of biologically active compounds such as proteins, peptides, synthetic chemical, or natural products compounds (e.g. doxorubicin as an antitumor agent and antifibrotic drug). Preferably, said biologically active compounds are cysteamine (CYS) as the aminothiol compound and one compound selected from the group consisting of doxorubicin (DOX), ketoprofen (KETO), or 4-hydroxybenzyl alcohol (HBA). Moreover, the simultaneous presence of both hydroxyl and carboxyl groups in the partially succinated polyvinyl alcohol (PVA-SA) chain of the prodrug enables the self-assembled formation of 50-260 nm particles from the linear macromolecules and thus the drug release can be prolonged or adjusted. The present invention also relates to improving the mucoadhesive properties of the polymeric prodrug by the regulation of the amount of conjugated aminothiol compound. Further, the present invention relates to the method for producing said mucoadhesive polymeric prodrug, and nanoparticles of the said mucoadhesive polymeric prodrug.

BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: US20260108473A1

0000 The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

PROTAMINE-COATED NUCLEIC ACID/THERAPEUTIC AGENT COMPLEXES, AND USES THEREOF

Resumen de: WO2025042791A1

The disclosure provides for compositions that comprise nanocomplexes formed by complexing one or more therapeutic agents with nucleic acid fragments of varying lengths and sizes that are coated or complexed with protamine sulfate, and uses thereof, including for the treatment of cancer in a subject in need thereof.

GOLF BALL-LIKE MICROPARTICLES FOR USE IN THE TREATMENT AND PREVENTION OF PULMONARY DISEASES

Resumen de: EP4729051A2

0001 The present invention relates to a method to prepare golf ball like microparticles by spray drying of nanosuspensions of nanoparticles or solutions for dry powder inhalers for use in the treatment and prevention of pulmonary diseases.

GRP78 TARGETED LIPOSOMAL NANOPARTICLES (TLNPS) FOR THE TREATMENT OF CANCER

Resumen de: WO2024259421A2

A nanoparticle generally comprising a targeting peptide-lipid conjugate, wherein a targeting peptide moiety of the targeting peptide-lipid conjugate comprises a GRP78 targeting peptide, a polyethylene glycol (PEG)-lipid conjugate, a drug-lipid conjugate comprising a prodrug moiety, wherein the drug-lipid conjugate comprises one or more of a mertansine (DM1) prodrug, a doxorubicin prodrug, and a bortezomib (BTZ) prodrug; and wherein the prodrug is linked to a lipid moiety of the drug-lipid conjugate via a phosphodiester bond or a boron ester bond; cholesterol comprising about 1 mol% to about 10 mol% of the nanoparticle; and distearoylphosphatidylcholine (DSPC).

NANOTUBE COMPOSITIONS AND METHODS FOR FACILIATING STEM CELL GROWTH

Resumen de: US2024417680A1

0000 The application pertains to compositions and methods useful for growing living cells such as stem cells. The compositions employ a mixture of an extracellular matrix and discrete carbon nanotubes. The extracellular matrix may also comprise components selected from the class of proteins, proteoglycans, polysaccharides, lipids, peptides, messenger molecules, signaling molecules, or any mixture thereof. The discrete carbon nanotubes are usually less than about 1% by weight of the dry weight of the total composition.

APOLIPOPROTEIN A-I NANODISKS FOR CENTRAL NERVOUS SYSTEM DELIVERY

Resumen de: WO2024254709A1

The present disclosure provides a therapeutic nanodisk, the therapeutic nanodisk comprising: a lipid-binding polypeptide; a lipid bilayer and a therapeutic agent, wherein the therapeutic agent may be of use for treating, preventing a central nervous system disease, disorder, trauma or injury; or as a diagnostic agent for diagnosing a central nervous system disease, disorder, trauma or injury. The lipid bilayer may be 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and the therapeutic agent may be a nucleic acid polymer. Further provided are methods for administration of the therapeutic nanodisk to treat, prevent or diagnose the central nervous system disease, disorder, trauma or injury and uses of such therapeutic nanodisks.

INTELLIGENT POLYMER-LIPID BASED NANO DRUG DELIVERY SYSTEM TO IMPROVE THE BBB-PENETRATION BY DUAL ACTIVE BRAIN TARGETING STRATEGIES

Resumen de: WO2024254703A1

The blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier (BCSFB) create an obstacle for effective systemic drug delivery to the CNS. This application provides compounds and nanoparticles for increasing the penetration of drugs through the BBB. Specifically, this application provides nanoparticles for the diagnosis and treatment of central nervous system (CNS) diseases and preparation methods therefor. These nanoparticles are polymer-lipid based nanoparticles (PLNPs) functionalized to facilitate blood brain barrier (BBB) penetration and accumulation in a disease area of the CNS. Notably, said nanoparticles target an LDL receptor and/or glucose transporter. In various embodiments, the nanoparticles comprise terpolymers which comprise polysorbates (such as polysorbate 80), poly acrylic acids (such as poly methacrylic acid (PMAA)) and various polysaccharides (including maltodextrin) and the nanoparticles also comprise cholesterol and lipids. The nanoparticles encapsulate a pay load which is a therapeutic drug molecule, biomolecule, contrast agent or nucleotide.

POLY(OXAZOLINE) CONJUGATES WITH PENDANT CATIONIC GROUPS AND LIPID NANOPARTICLES AND POLYPLEXES INCLUDING SAME

Resumen de: WO2024259281A2

Poly(oxazoline) conjugates with pendant cationic groups (cationic POZ) and lipid nanoparticles (LNPs) including cationic POZ used to facilitate delivery of an encapsulated payload. LNPs and polyplexes including cationic POZ and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing an ionizable lipid.

METHODS FOR PROVIDING INTERCELLULAR COMMUNICATION

Resumen de: WO2024259374A2

To introduce material to cells, contemporary medicinal constructs rely on the uptake mechanisms of the cell membrane. This puts major restrictions on the types of utilizable materials (e.g., charge compatible), specifications (e.g., 100 nanometer scale or less) and organizations (mostly simplistic spheroids); this is the regime of nanoparticles, protein/peptide conjugates etc. However, the focus and novelty of the innovation presented are constructs which can still achieve this membrane interaction to connect to cells yet the constructs themselves remain outside of the cell, thus establishing a network by which to transfer materials. These can surpass the aforementioned limitations as well as create entirely new application spaces as these new constructs enable different desired distribution patterns and exchanged material.

SYSTEMS, METHODS, AND COMPOSITIONS FOR DE-REPRESSING PKD1

Resumen de: WO2024259175A2

Provided herein is a system for inhibiting a miRNA-17 family miRNA from binding to the 3'UTR of PKD1, where the system includes: a gRNA; and a polynucleotide-programmable nucleotide-binding domain, where the system modifies a binding site of a miRNA-17 family miRNA in the 3'UTR of PKD1, thereby preventing binding of the miRNA-17 family miRNA and de-repressing PKD1 mRNA.

COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS

Resumen de: WO2024259373A1

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel cationic lipid as well as additional lipids such as ionizable lipids, phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

MIXED AMIDE ESTER CONTAINING LIPIDS FOR USE IN LIPID NANOPARTICLES

Resumen de: WO2024259356A1

Compounds are provided having the following Formula (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, G2, R1, R2, R3, L1a, L1b, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

EPIGENETIC EDITING TOOL FOR TARGETING HEPATITIS B VIRUS GENE

Resumen de: EP4729075A1

0001 The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.

METHOD FOR STABILIZING RNA

Resumen de: WO2024256962A1

The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.

LIPIDS FOR USE IN LIPID NANOPARTICLES

Resumen de: WO2024259322A1

Compounds are provided having the following Formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, G1, G2, L1, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

AMIDE CONTAINING LIPIDS

Resumen de: WO2024259315A1

Compounds are provided having the following Formula (I): (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, R1, R2, R3, L1, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

RAPIDLY-METABOLIZED LIPID COMPOUND

Resumen de: EP4729507A1

Provided is a rapidly-metabolized lipid compound. The present invention relates in particular to a compound represented by formula (I), or a pharmaceutically acceptable salt, an isotopic variant, a tautomer or a stereoisomer thereof. Also provided are a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and a composition thereof in delivering nucleic acids.

均一なナノ粒子製造のためのマイクロ流体装置

Resumen de: KR102631907B1

The present invention relates to a device useful for manufacturing nanoparticles containing hydrophobic substances and hydrophilic substances. Specifically, the device of the present invention comprises: a plurality of inlet channels through which hydrophobic substances and hydrophilic substances are respectively introduced; a mixing channel through which the substances are mixed to manufacture nanoparticles; and an outflow channel through which the manufactured nanoparticles are discharged, wherein the mixing channel includes micro-pillars capable of increasing the mixing efficiency of the substances. Therefore, the nanoparticles manufactured by the device of the present invention have excellent particle uniformity and may be usefully used as drugs or drug delivery vehicles.

IMMUNOSORBENT NANOPARTICLES AND METHODS OF USING THEREOF

Resumen de: WO2024258949A2

Disclosed herein are immunosorbent nanoparticles, devices, and methods for selective removal of a target protein such as beta-2 microglobulin (B2M) from a liquid such as blood.

包封有核酸的配体修饰脂质纳米颗粒的制造方法

Resumen de: WO2025063214A1

The present invention provides a method for producing ligand-modified lipid nanoparticles encapsulating a nucleic acid, said method comprising the following steps a) to c), etc.　Step a) Mixing an alcohol solution comprising an ionic lipid, a sterol, and a PEG lipid with an acidic buffer solution having a pH of 1-6.5, thereby obtaining a suspension of lipid nanoparticles that do not include a nucleic acid. Step b) Mixing the lipid nanoparticles that do not include a nucleic acid with a nucleic acid solution, thereby obtaining a suspension of lipid nanoparticles that encapsulate a nucleic acid. Step c) Mixing the suspension of lipid nanoparticles that encapsulate a nucleic acid with a ligand-bonded lipid, thereby obtaining a suspension of ligand-modified lipid nanoparticles that encapsulate a nucleic acid.

抗体偶联物、相关的药物组合物及应用

Resumen de: WO2018137609A1

The present invention provides a multispecific antibody conjugate (i.e., a bispecific antibody conjugate), and a related composition, therapeutic method and use thereof. The antibody conjugate comprises a multispecific antibody coupled on a nano material, such as a bispecific antibody. The antibody conjugate can be used for regulating immune responses and treating or preventing diseases and disorders (such as cancers, autoimmunity diseases, pathogen infection, or inflammatory diseases).

一种F4/80抗体偶联的脂质纳米颗粒及其制备方法及其应用

Nº publicación: CN121891554A 21/04/2026

Solicitante:

福建医科大学附属协和医院

Resumen de: CN121891554A

本发明属于纳米材料技术领域，具体涉及一种F4/80抗体偶联的脂质纳米颗粒及其制备方法及其应用。所述F4/80抗体偶联的脂质纳米颗粒包括脂质纳米粒和巯基修饰的F4/80抗体；将所述巯基修饰的F4/80抗体偶联在所述脂质纳米粒上；所述脂质纳米粒与所述巯基修饰的F4/80抗体的摩尔比为3~5：1；所述巯基修饰的F4/80抗体为F4/80抗体引入巯基后得到的改造后的抗体；所述F4/80抗体的氨基酸序列如SEQ ID NO.1所示；所述脂质纳米粒是以单磷酰脂质A作为佐剂，同时负载IFNγ mRNA的纳米粒。本发明提供的该F4/80抗体偶联的脂质纳米颗粒能够提高脂质纳米颗粒体内体外的靶向性和转染效率。